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Abstract
Background: One of the greatest success of pediatric hematology is a prominent improvement of survival in acute
lymphoblastic leukemia (ALL). Therefore, special attention needs to be paid to long-term side effects of the
treatment such as neurotoxicity. One of the few diagnostic methods that allow an objective assessment of sensory
systems are evoked potentials (EP).
Methods: The analyzed group consisted of 167 ALL long-term survivors, aged 4.9–28.4 years, without auditory,
visual and sensory deviations. Patients were treated with New York (NY, n = 35), previous modified Berlin-Frankfurt-
Münster (pBFM, n = 47) and BFM95 (n = 85) protocols. In order to assess the impact of radiotherapy on recorded EP,
a joint analysis of NY and pBFM groups was performed. The control group consisted of 35 patients, aged 6–17
years. The analyzed patients underwent a complex assessment with visual EP (VEP), somatosensory EP (SEP) and
brainstem auditory EP (BAEP) in accordance with current standards.
Results: ALL treatment contributed to the shortening of wave I latency (1.59 vs 1.90, P = 0.003) and prolongation of
I-III (2.23 vs 2.04, P = 0.004) and I-V (4.57 vs 4.24, P = 0.002) interwave latencies of BAEP. A significant effect was also
noticed in P100 (106.32 vs 101.57, P < 0.001) and N135 (151.42 vs 138.22, P < 0.001) latencies of VEP and N18 amplitude
(3.24 vs 4.70, P = 0.007) and P25 latency (21.32 vs 23.39, P < 0.001) of SEP. The distribution of abnormalities between
protocols was similar in BAEP (NY - 68.6%, pBFM - 61.7%, BFM95–69.4%, P = 0.650), VEP (NY - 68.6%, pBFM - 42.5%,
BFM95–58.3%, P = 0.053) and significantly different for SEP (NY - 62.9%, pBFM - 36.2%, BFM95–53.0%, P = 0.045). The
harmful effect of radiotherapy was most clearly marked in numerous disturbances of SEP parameters.
Conclusions: The presented analysis indicates a high frequency of subclinical abnormalities in EP regardless of the
analyzed protocol. To our knowledge current study is the largest and one of the most complex research examining the
role of EP in ALL patients. The obtained results indicate the possibility of using a single, objective and non-invasive
measurement of EP in ALL survivors in order to stratify the risk of developing sensory abnormalities in adulthood.
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Background
One of the greatest success of pediatric hematology is a
prominent improvement of survival in acute lympho-
blastic leukemia (ALL), which is precisely related with
introduction of new therapeutic regimens [1]. Nowadays
ALL therapeutic protocols consisted mainly of chemo-
therapy and exceptionally radiotherapy which is associ-
ated with potential severe adverse effects. Those factors
may lead also to significant changes in the nervous sys-
tem. According to the fact that ALL is the most com-
mon type of cancer in a pediatric population, long-term
results of the treatment represent an important social
problem [2]. Improvement of survival rates encourage to
focus on long-term side effects of the treatment and as-
sociated with them quality of life.
Child development is a complex process with an im-
portant role of sensory systems. As established earlier,
the development of individual senses begins in the early
fetal life and is stimulated by various endo- and exogen-
ous stimuli [3]. Adequate sensual growth is crucial for
the child’s further development. To date, a number of
non-inherited, postnatal factors have been associated
with an adverse effect on the hearing, vision and sensory
perception development [3]. One of them is undoubtedly
intensive anticancer treatment in patients with ALL.
Currently used anticancer regimens impair various func-
tional cognitive processes in ALL survivors [4]. Signifi-
cant changes in the central nervous system such as
smaller volumes of neocortical and subcortical gray mat-
ter have been demonstrated using magnetic resonance
methods [5]. However, clinically observed hearing, vision
or sensory impairment in ALL survivors that may be as-
sociated with anticancer treatment is rare [6].
One of the few diagnostic methods that allow an ob-
jective assessment of individual senses, as well as the
whole integrated development of sensory organization
are evoked potentials (EP). EP are defined as specific re-
sponses to selected, sensory stimuli and may be non-
invasively recorded. Multiple types of exogenous, sen-
sory modality can be measured with different modifica-
tions of this technique: visual evoked potentials (VEP),
somatosensory evoked potentials (SEP), brainstem audi-
tory evoked potentials (BAEP). Peak amplitudes and la-
tencies of particular waves are analyzed in detail [7]. In
our previous study we reported that abnormal BAEP can
be registered in 22.4% of children treated for ALL [8].
As previously shown by Kaleita et al. [9], Russo et al.
[10], Muchi et al. [11] and Korinthenberg et al. [12] ab-
normalities in EP analysis can be found in a significant
proportion of ALL patients. However, there were also
some reports in the literature questioning the clinical
usefulness of EP in this group of patients [13, 14].
The aim of our study was to conduct and verify the
clinical utility of complex neurophysiologic evaluation
using different types of EP in group of childhood ALL
survivors treated with various protocols.
Methods
A group of 167, 103 males, aged 4.9–28.4 years who have
completed ALL therapy was enrolled to the study. The
mean patients age at diagnosis was 5.3 ± 3.5 and 13.9 ±
5.3 at neurophysiological assessment. The time between
the end of treatment and the study varied from 0.3 to
20.9 years. Patients at study.The study group was divided
into 3 subgroups according to treatment protocols intro-
duced gradually by Polish Leukemia/Lymphoma Study
Group. The first group consisted of 35 patients (21 boys,
60%) who received treatment according to modified
New York programs (NY). The second group of 47 pa-
tients (24 boys, 51.1%) was treated with previously modi-
fied BFM protocols (pBFM): BFM 81, 83, 86 and 87
(Table 1). In those two groups optionally, therapeutic
central nervous system radiotherapy was conducted. The
last group of 85 patients (40 males, 47.1%) underwent
treatment with BFM95 protocol without radiotherapy.
There were no symptoms of hearing, sight and sensory
perceptions disorders in participants. ALL relapse has
not been registered in the study population. The central
nervous system involvement was confirmed in 7 cases (1
– NY, 5 – pBFM and 1 – BFM95, respectively).
Average cumulative dose of vincristine in NY proto-
cols was 60.8 mg/m2 and 30 mg/m2 in BFM protocols re-
spectively. The radiotherapy dose in pBFM group was
13–36.4 Gy (mean 18.4 Gy), while in the group treated
with NY protocols - 18.2-24 Gy (mean 18.3 Gy). It was
the whole brain irradiation to the C2 region including
retroocular and bases of frontal regions areas. Exclusion
criteria from the study were other diagnoses than ALL,
patients with primary neurologic diseases and/or inborn
genetic defect (Table 2).
The control group consisted of 45 patients (23 males,
51.4%), aged 6–17(mean 11,6 ± 3,6) years. They were pa-
tients of Neurology Department inpatient and out-
patient, and Outpatient Orthopedic Department of
University Children’s Hospital (children with educational
difficulties, emotional disorders, children after a single
syncope episode) and general healthy volunteers which
were neurologically consulted.
The performed studies were as follow: BAEP – 25,
VEP - 32, and SEP- 30. No patient in the study and con-
trol groups was diagnosed with focal CNS symptoms, in






MTX doses in consolidation 1 g/m2 3 g/m2
Prophylactic radiotherapy 18Gy –
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all psychomotor development were in normal range. No
one was treated for at least 1 week before neuro-
physiological evaluation. They attendant schools accord-
ing to age.
The evoked potentials evaluations were performed ac-
cording to IFCN recommendations. The patients were
studied in comfortable half-siting position. All were ex-
amined in the same room with the use of the same
equipment by the same technician. The external condi-
tions were limited with the use of air-conditioner keep-
ing the same temperature and humidity. The obtained
data were evaluated by the same physician.
The study protocol was complied with the Declaration
of Helsinki and was approved by the Jagiellonian Univer-
sity Medical College Ethics Committee (Consent No.
KBET/131/B/207). All parents as well as adolescent and
adult patients signed written informed consent before
inclusion in the study.
Auditory evoked potentials methodology
Examination was performed in comfortable semi-sitting
position on armchair with back and head support. The
stimulation was performed by headphones with use an
acoustic impulse. At first, an electrophysiological hearing
threshold was estimated. Next, both ear canals were
stimulated alternately with repetitive (10 Hz) acoustic
stimulus (click) at 70 dB above hearing threshold. During
it other ear was masked by murmur at 40 dB lower than
acoustic stimulus. BAEP were recorded by using cup
electrodes placed according to 10–20 international sys-
tem. Detected waves were analyzed by comparing im-
pulses from stimulated or not stimulated ear with those
from a vertex. Used filter excluded frequencies below
150 Hz and above 300 Hz. Recorded 1000–2000 re-
sponses were averaged twice. According to guidelines of
International Federation of Clinical Neurophysiology
(IFCN) only curves with differences less than 0.1 ms in
latencies and less than 10% in amplitudes between waves
were taken into consideration. Waves I, III and V, their
latencies and also interwave latencies between waves I-
V, I-III, III-V were evaluated. Recorded results were
compared with normal values based on our own data.
Latencies and interwave latencies elongation more than
2 SD were considered as abnormal (Figs. 1 and 2). To
evaluate the effect of treatment, comparisons of ALL pa-
tients (NY, pBFM, BFM95) were made with the control
group. Additionally, to evaluate impact of radiotherapy a
group of patients receiving radiotherapy (NY and pBFM)
was compared to non-irradiated (BFM95).
Visual evoked potentials methodology
All patients were examined in comfortable position in
shady room (about 50 lx). Before examination all pa-
tients have been evaluated for visual acuity. VEP were
examined according to IFCN guidelines with using “pat-
tern reversal” method. Black and white checkerboard
pattern with specified dimension as 16 min of arc, was
moving in sequence with frequency of 2 Hz. A monitor
was 1 m in front of patient’s eyes. Average luminance of
stimulator in middle of a stimulation area was 50 cd/m2.
In study were used: Recording electrode placed in mid-
dle of occipital area, references electrodes in middle line
on forehead in first scheme and two on auricles in the
others and zero electrode on vertex. Used filter excluded
frequencies below 0.3 Hz and above 300 Hz. Time of
analysis was from 250 to 450ms. At least 100 measure-
ments were averaged. From obtained curve, positive
(N70, N135) and negative (P100) were isolated for fur-
ther analysis of their latencies and amplitudes. Only
pairs of curves were evaluated in which the latency of
the P100 wave did not differ by more than 2.5 ms (Figs. 3
and 4).
Somatosensory evoked potentials methodology
The SEP analysis was performed in accordance with
IFCN recommendations. The median nerve was stimu-
lated with repeated rectangular electric stimulus from
electrode placed over the wrist area, with duration of
200 μs, frequency 5 Hz and intensity exceeding 3 times
the threshold stimulus causing the sensory response. Re-
sponse was recorded by 4 cup electrodes. In every case,
before stimulation an electrode resistance was measured
(lower than 500Ω). Recorded frequencies below 20–30
Hz and above 3000 Hz were excluded. Average time of









Age at diagnosis, years 6.5 ± 0.5 4 ± 2.7 5 ± 2.6 –
Age at study, years 14 ± 5.6 18.3 ± 4.2 11.4 ± 4.1 11.6 ± 3.6
Median CRT dose, Gy 18.4 18.3 – –
CNS involvement, N 1 5 1 –
Average cumulative VCR dose, mg/m2 60,8 30 30 –
Symptoms of hearing, sight and sensory perceptions disorders No No No No
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol, CRT cranial radiotherapy, VCR vincristine
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Fig. 1 Normal BAEP in 10 y.o. boy
Fig. 2 BAEP with elongation of wave V in 10 y.o. boy after ALL treatment
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analysis was 50 ms. Depending on the legibility of the
waves, 500–2000 responses were averaged. In every case
2 similar entries were recorded in which the latency dif-
fer not more than 0,25 ms and amplitudes no more than
20%. Amplitudes and latencies of above described waves
were analyzed and compared to control group. Periph-
eral (PCT) and central (CCT) conduction times were es-
timated for differentiation. Results of examination was
compared to our normal values based on own material.
SEP waves with latency and interlatency elongation more
than 2 SD and/or amplitudes less than 1 SD were as-
sumed as abnormal (Figs. 5 and 6). P14 waves were not
analyzed due to high variability in the control group.
Statistical analysis
Statistical analyses were performed with Statistica 12.0
(StatSoft, Statistica 12.0, Tulsa, Oklahoma, USA) soft-
ware. Continuous variables were expressed as mean ±
standard deviation and categorical variables as number
(percentage). Continuous variables were first checked for
normal distribution by the Shapiro-Wilk statistic. Differ-
ences among two groups were compared by student’s t-
test when normally distributed or by the Mann-Whitney
test with test for non-normally distributed variables. In
turn, differences among the three groups were compared
by ANOVA test when normally distributed or by the
Kruskal-Wallis test with test for multiple comparisons
for non-normally distributed variables. Categorical vari-
ables were analyzed by the chi-square test and Fisher’s
exact test depending on the size of the analyzed groups.
P-value of less than 0.05 was considered statistically
significant.
Results
Significant age differences were observed in terms of
treatment introduction and neurological control. Pa-
tients from pBFM group were significantly the youngest
at the start of treatment (mean age 4.0 ± 2.7 years, P <
0.001). On the other hand, at the moment of neuro-
logical evaluation they were the oldest (18.3 ± 4.2 years,
P < 0.001). Mean age of treatment introduction was
6.5 ± 0.5 years in NY and 5.0 ± 2.6 years in BFM95 and
age of study - 14.0 ± 5.6 and 11.4 ± 4.1 years, respectively.
Moreover, mean age of the control group was 11.6 ± 3.6
years and was significantly lower than age of ALL pa-
tients at study (13.9 ± 5.3 years, P = 0.016). However, we
Fig. 3 Normal VEP in 7 y.o. girl
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did not observe significant differences in term of gender
distribution.
Analysis of auditory evoked potentials in the study
groups
Introduction of an oncological treatment contributed to
observed shortening of latency of I wave (1.59 vs 1.90,
P = 0.003) and to the prolongation of I-III interwave la-
tency (2.23 vs 2.04, P = 0.004) and I-V (4.57 vs 4.24, P =
0.002) interwave latencies. Similar frequency of abnor-
malities in each protocol was observed (NY – 68.6%,
pBFM – 61.7%, BFM95–69.4%). Moreover, there were
no significant differences in frequency of wave and inter-
wave latencies elongation between treatment groups
(Table 3). Only average of interwave I-V latency in ALL
survivor were significant longer than in control group
(P = 0.035). Similar relationships were observed in add-
itional comparison NY vs control group (P = 0.002) and
BFM95 vs control group (P = 0.011). However, the la-
tency of wave I was significantly longer in control group
than in others.
Analysis of visual evoked potentials in the study groups
Due to technical difficulties, the examination was not
performed in one patient from the BFM95 group. Direct
comparison of the whole ALL survivors group to the
control group revealed significant elongation of P100
(106.32 vs 101.57, P < 0.001) as well as N135 (151.42 vs
138.22, P < 0.001) latencies in the first one. Moreover,
diffierences in total number of stated abnormalities were
not observed (NY – 68.6%, pBFM – 42.5%, BFM95–
58.3%). Analysis of examined VEP showed no significant
differences between groups of patients after ALL treat-
ment in occurrence of N70, P100 and N135 latency pro-
longation (Table 4). A significant difference was
observed in a P100 amplitude decrease (P = 0.001). It
was more often stated in the NY group (17.1%) than in
others (pBFM - 2.1%, BFM - 0%). More distinctions were
observed in comparison of average values to control
group. Latencies of P100 (P = 0.005) and N135 (P <
0.001) were significantly longer in particular groups after
ALL treatment. Noteworthy, P100 amplitude in BFM95
was significantly higher than in other treatment groups
and control (P = 0.019).
Fig. 4 Abnormal VEP in 9 y.o. boy after ALL treatment
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Analysis of somatosensory evoked potentials in the study
groups
Due to technical difficulties, the examinations were not
performed in two patients from the BFM95 group. Ana-
lysis of a total ALL group revealed that the anticancer
treatment had a direct impact on amplitude reduction of
N18 (3.24 vs 4.70, P = 0.007) and shortening of P25 la-
tency (21.32 vs 23.39, P < 0.001). Moreover, there was
also a significant difference in a total number of abnor-
malities between groups (NY – 62.9%, pBFM – 36.2%,
BFM95–53.0%, P = 0.045). In collected data abnormal
low amplitude was significantly most often in pBFM
group for N13, N20, P25 and in BFM95 for N9. An oc-
currence of N18 amplitude decrease was comparable
(P = 0.279). Abnormal prolonged latency was observed
for N13 (P = 0.005) and N18 (P < 0.001) only in NY
group. For other analyzed waves it was not observed.
Next, average values of amplitude and latencies for each
feature were compared to control group. N18 amplitude
was significantly lower in ALL survivors groups than in
control (P = 0.001). However, patients in control group
had significantly longer P25 latency than groups after
treatment (P < 0.001). Moreover suchlike relationship
was observed in comparison of control to specific treat-
ment group: NY vs control (P < 0.001), pBFM vs control
(P < 0.001), BFM95 vs control (P < 0.001). Conduction
times for PCT and CCT were not significantly often pro-
longed between ALL survivors groups and not signifi-
cantly longer in comparison to the control group
(Table 5).
Impact of radiotherapy on evoked potentials
To evaluate the effect of radiotherapy on EP, additional
analysis was performed in above-mentioned alternative
groups (NY + pBFM vs BFM95). There were no signifi-
cant differences in the summary recorded features of
particular EP (BAEP: 64.6 vs 69.4%, VEP: 53.7 vs 58.4%,
SEP: 47.6 vs 53.0%). Moreover, significant differences
were also not observed in BAEP parameters between
compared groups (Table 6). However, the conducted
analysis of VEP has shown that in NY + pBFM group,
amplitude of P100 was significantly more often de-
creased (8.5 vs 0%, P = 0.006) and P100 amplitude mean
value was significantly lower (9.61 vs 12.46, P = 0.004)
Fig. 5 Normal SEP in 15 y.o. boy
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Fig. 6 Abnormal SEP with prolonged N9 latency in 13 y.o. boy after ALL treatment
Table 3 Auditory evoked potentials in the study groups
NY pBFM BFM95 Control P value
Prolonged latency of wave I 3 (8.6) 4 (8.5) 6 (7.1) – 0.872
Prolonged latency of wave III 5 (14.3) 10 (21.3) 21 (24.7) – 0.406
Prolonged latency of wave V 5 (14.3) 9 (19.2) 14 (16.5) – 0.658
Prolonged interwave I-III latency 13 (37.1) 13 (27.7) 29 (34.1) – 0.795
Prolonged interwave III-V latency 10 (28.6) 16 (34.0) 28 (32.9) – 0.610
Prolonged interwave I-V latency 17 (48.6) 17 (36.2) 44 (51.8) – 0.307
Latency of wave I 1.52 1.75 1.64 1.91 0.001*
Latency of wave III 3.82 3.96 3.87 3.98 0.615
Latency of wave V 6.14 6.27 6.14 6.16 0.990
Interwave I-III latency 2.21 2.19 2.26 2.04 0.081
Interwave III-V latency 2.33 2.33 2.34 2.20 0.562
Interwave I-V latency 4.58 4.52 4.59 4.24 0.035
* NY vs control P = 0.002, BFM95 vs control P = 0.011
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol
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Table 4 Visual evoked potentials in the study groups
NY pBFM BFM95 Control P value
Prolonged N70 latency 6 (17.1) 3 (6.4) 6 (12.2) – 0.375
Prolonged P100 latency 13 (37.1) 10 (21.3) 31 (63.3) – 0.541
Decreased P100 amplitude 6 (17.1) 1 (2.1) 0 (0.0) – 0.001
Prolonged N135 latency 22 (62.9) 17 (36.2) 43 (87.8) – 0.786
N70 latency 71.82 69.35 69.62 70.71 0.355
P100 latency 107.23 103.86 107.32 101.62 0.005*
P100 amplitude 10.17 9.24 12.55 12.31 0.019
N135 latency 152.17 148.18 153.03 138.22 < 0.001**
* NY vs control P = 0.050, BFM95 vs control P = 0.044
** NY vs control P = 0.001, pBFM vs control P = 0.028. BFM95 vs control P < 0.001
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol
Table 5 Somatosensory evoked potentials in the study groups
NY pBFM BFM95 Control P value
Prolonged N9 latency 0 (0.0) 0 (0.0) 0 (0.0) – –
Decreased N9 amplitude 0 (0.0) 10 (21.3) 18 (21.7) – < 0.001
Prolonged N13 latency 4 (11.4) 0 (0.0) 0 (0.0) – 0.005
Decreased N13 amplitude 0 (0.0) 7 (14.9) 4 (4.8) – 0.018
Prolonged P14 latency 3 (8.8) 2 (4.3) 4 (4.8) – 0.930
Prolonged N18 latency 20 (57.1) 0 (0.0) 0 (0.0) – < 0.001
Decreased N18 amplitude 14 (40.0) 17 (36.2) 22 (26.5) – 0.279
Prolonged N20 latency 2 (5.7) 0 (0.0) 2 (2.4) – 0.250
Decreased N20 amplitude 0 (0.0) 7 (14.9) 4 (4.8) – 0.018
Prolonged P25 latency 0 (0.0) 0 (0.0) 0 (0.0) – –
Decreased P25 amplitude 0 (0.0) 7 (14.9) 4 (4.8) – 0.018
Prolonged PCT 3 (8.8) 1 (2.1) 8 (9.6) – 0.270
Prolonged CCT 3 (8.8) 2 (4.3) 7 (8.4) – 0.642
N9 latency 9.18 9.21 8.75 9.22 0.010
N9 amplitude 5.26 6.10 6.98 6.15 0.030
N13 latency 12.19 12.13 11.73 11.95 0.137
N13 amplitude 2.27 2.37 3.16 2.88 0.223
P14 latency 13.67 13.80 13.39 13.17 0.170
P14 amplitude 1.80 2.17 1.73 2.12 0.695
N18 latency 16.69 16.94 16.50 17.17 0.117
N18 amplitude 3.12 2.53 3.70 4.70 0.001*
N20 latency 18.39 18.21 17.75 17.95 0.070
N20 amplitude 1.86 1.66 1.72 2.24 0.356
P25 latency 21.65 21.25 21.22 23.39 < 0.001**
P25 amplitude 3.88 3.58 3.90 4.43 0.600
PCT 3.01 2.91 2.97 2.73 0.467
CCT 6.20 6.09 6.03 6.00 0.882
* NY vs control P = 0.042, pBFM vs control P = 0.002
** NY vs control P < 0.001, pBFM vs control P < 0.001, BFM95 vs control P < 0.001
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, CCT central conduction time, NY New York protocol, PCT peripheral conduction time
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(Table 7). Other analyzed features of VEP were compar-
able between groups. Finally, the effect of radiotherapy
on SEP was investigated (Table 8). Patients treated with
radiotherapy significantly more frequently represented a
prolonged N18 latency (24.4 vs 0%, P < 0.001). Also the
mean value of N18 amplitude was significantly lower in
NY + pBFM group (P = 0.009). However, direct compari-
son has shown that in group BFM95 (21.7%) amplitude
of N9 was (P = 0.042) decreased more often than in joint
group with radiotherapy (12.2%). Further analyses shown
that in NY + pBFM group latencies were significantly
longer in: N9 (P = 0.002), N13 (P = 0.018), N20 (P =
0.012). It corresponds with significant reduction of amp-
litude for: N9 (P = 0.007), N13 (P = 0.038), N18 (P =
0.009).
Discussion
The aim of our study was to present the possibilities of
complex EP analysis application in a large group of 167
ALL long-term survivors. As we have shown, the onco-
logical treatment had a significant impact on the shape
of registered EP. The disturbances, mainly in the form of
longer conduction time, were recorded in a significant
percentage of patients in each of the analyzed protocols.
As we have already emphasized above, the impact of
radiotherapy used in NY and pBFM protocols was most
clearly marked in SEP analysis. According to our know-
ledge, our study is the largest study dedicated to the
issue of EP in ALL survivors so far. Also, the analyzed
follow-up time was one of the longest in literature.
Moreover, our study is only the third report on the sim-
ultaneous analysis of several EP types in one
homogenous ALL study group.
Published EP studies have not consolidated their final
position in the diagnosis of ALL survivors. As we men-
tioned earlier, only few studies presenting complex as-
sessment with different types of EP can be found in the
literature [9, 11, 12]. Kaleita et al. [9] found
Table 6 Auditory evoked potentials in irradiated and non-
irradiated groups
NY + pBFM BFM95 P value
Prolonged latency of wave I 7 (8.5) 6 (7.1) 0.722
Prolonged latency of wave III 15 (18.3) 21 (24.7) 0.314
Prolonged latency of wave V 14 (17.1) 14 (16.5) 0.917
Prolonged interwave I-III latency 26 (31.7) 29 (34.1) 0.740
Prolonged interwave III-V latency 26 (31.7) 28 (32.9) 0.865
Prolonged interwave I-V latency 34 (41.5) 44 (51.8) 0.182
Latency of wave I 1.61 1.57 0.621
Latency of wave III 3.82 3.84 0.776
Latency of wave V 6.15 6.14 0.909
Interwave I-III latency 2.20 2.26 0.367
Interwave III-V latency 2.33 2.34 0.889
Interwave I-V latency 4.55 4.59 0.646
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol
Table 7 Visual evoked potentials in irradiated and non-
irradiated groups
NY + pBFM BFM95 P value
Prolonged N70 latency 9 (11.0) 6 (12.2) 0.389
Prolonged P100 latency 23 (28.1) 31 (63.3) 0.223
Decreased P100 amplitude 7 (8.5) 0 (0.0) 0.006
Prolonged N135 latency 39 (47.6) 43 (87.8) 0.640
N70 latency 70.37 69.58 0.485
P100 latency 105.27 107.34 0.158
P100 amplitude 9.61 12.46 0.004
N135 latency 149.78 153.01 0.171
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol
Table 8 Somatosensory evoked potentials in irradiated and
non-irradiated groups
NY + pBFM BFM95 P value
Prolonged N9 latency 0 (0.0) 0 (0.0) –
Decreased N9 amplitude 10 (12.2) 18 (21.7) 0.042
Prolonged N13 latency 4 (4.9) 0 (0.0) 0.339
Decreased N13 amplitude 7 (8.5) 4 (4.8) 0.339
Prolonged P14 latency 5 (6.1) 4 (4.8) 0.717
Prolonged N18 latency 20 (24.4) 0 (0.0) < 0.001
Decreased N18 amplitude 31 (37.8) 22 (26.5) 0.120
Prolonged N20 latency 2 (2.4) 2 (2.4) 0.989
Decreased N20 amplitude 7 (8.5) 4 (4.8) 0.339
Prolonged P25 latency 0 (0.0) 0 (0.0) –
Decreased P25 amplitude 7 (8.5) 4 (4.8) 0.339
Prolonged PCT 4 (4.9) 8 (9.6) 0.239
Prolonged CCT 5 (6.1) 7 (8.4) 0.563
N9 latency 9.20 8.75 0.002
N9 amplitude 5.74 6.98 0.007
N13 latency 12.15 11.73 0.018
N13 amplitude 2.32 3.16 0.038
P14 latency 13.74 13.39 0.100
P14 amplitude 2.01 1.73 0.429
N18 latency 16.83 16.50 0.139
N18 amplitude 2.78 3.70 0.009
N20 latency 18.29 17.75 0.012
N20 amplitude 1.74 1.72 0.924
P25 latency 21.42 21.22 0.460
P25 amplitude 3.71 3.90 0.639
PCT 2.95 2.97 0.857
CCT 6.14 6.03 0.564
Abbreviations: BFM Berlin-Frankfurt-Münster protocol, CCT central conduction
time, NY New York protocol, PCT peripheral conduction time
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abnormalities in individual EP in a significant percentage
of patients (50% - VEP, 41.7% - BAEP, 36.4% - SEP).
However, their analyses were based on both patients
with ALL as well as with acute myeloblastic leukemia
qualified for bone marrow transplantation. Muchi et al.
[11] conducted their study on a homogeneous group of
ALL patients who survived at least 2 years since the end
of oncological treatment. The small group of 28 partici-
pants, however, makes it impossible to draw final con-
clusions and this report should be interpreted as a
preliminary observation. The study by Korinthenberg
and Igel [12] on 79 ALL patients who completed anti-
cancer treatment at least 18 months earlier has been the
most comprehensive report to date. As observed,
changes in VEP and BAEP were transient and regressed
after the observation period. Moreover, no significant
differences were found between irradiated and non-
irradiated patients. The most important report for VEP
was the study by Russo et al. [10]. The delay in conduct-
ivity in VEP analysis in almost all asymptomatic patients
who received radiotherapy created the basis for further
research on this phenomenon. Much fewer reports in
the literature concerned the use of BAEP. One of them
is our report from 2006, which showed the presence of
abnormalities in 22.4% of asymptomatic ALL patients
[8]. Moreover, the role of SEP in ALL patients has been
extensively studied in Finnish centers [15–17]. The
neurotoxic effects of vincristine and intrathecal metho-
trexate have been demonstrated several times in various
parts of the nervous system.
According to the literature BAEP is highly sensitive in
detection of nerve VIII tumors, abnormalities were no-
ticed in above 90% of patients with acoustic neurinoma.
BAEP abnormalities observed in acoustic neurinoma and
cerebellopontine angle tumors oscillate from elongation
of interlatencies of I-III waves (what indicates conduc-
tion delay between distal part of VIII nerve and lower
part of the pontine) to disappearance of the components
of the response III and V, or total disappearance of all
components. Other changes of SPWPM parameters were
observed in patients with neoplastic diseases and with-
out structure brain stem damage [12, 18–20]. In patients
with ALL in treatment subgroups all interlatencies were
elongated. Although statistically significant differences
between groups were noticed only in interlatencies I-V
(in ANOVA and Kruskal-Wallis tests), in other tests the
significant differences were not observed in comparison
between studied subgroups and subgroups and control.
Clear evidence in ALL group showing slowing of the
conductivity of auditory stimuli in CNS, was significant
elongation of interlatencies I-III and I-V in comparison
to control. Another interesting observation was elong-
ation of BAEP latency and interlatency observed slightly
more often in patients treated according to BFM 95
protocol (69,41%), what can be explained by shorter time
interval between completion of therapy and testing. Of
importance seems to be the observation that was no sta-
tistically significant influence of radiotherapy on BAEP
parameters. The obtained data should be treated with
caution. High prevalence of patients with detected
elongation of BAEP parameters did not translate into
significant increase of mean latency BAEP parameters.
In the context of our results it seems that measurements
of I-V interlatencies are the best markers in neuro-
physiological assessment of hearing impairment in pa-
tients treated because of ALL.
Uberall et al. [14] shown that frequency and severity
VEP changes in patients with and without radiotherapy
was similar. This is in a discrepancy with our results in-
dicating significant unfavorable influence of radiotherapy
on P100 potential amplitude value.
In our study abnormalities of VEP parameters were
shown in 93 (56%) of patients treated due to ALL and
the most often with NY protocols. Radiotherapy had not
significantly important adverse influence on lowering the
amplitude of the P100 wave, however, it had no also ad-
verse effect on elongation of its latency. An interesting
observation seems to be the fact that N135 latency was
significantly longer between ALL subgroups than in
comparison between all studied ALL subgroups and
control group. In turn, of statistical analysis of SEP did
not confirmed preliminary observations suggesting sig-
nificant elongation of central conduction time (CCT)
published previously, which probably resulted from the
smaller size of the group assessed at that time. Ultim-
ately, however, a slight prolongation of PCT and CCT
depending on the intensity of the therapeutic program
was demonstrated in comparison of all studied sub-
groups and control. A similar relationship could be seen
in most mean SEP between patients treated with radio-
therapy and BFM95 (without radiotherapy). Our data is
in accordance with observed by Vainionpää et al. [15],
who studied SEP in 38 children with ALL, elongations of
PCT time were observed in the group of children with
standard, medium and high risk.
It can be stated that the most frequently used argu-
ment in studies negating the usefulness of the EP ana-
lysis in ALL patients is the lack of their translation into
the abnormalities found in the physical examination [13,
14]. This lack of correlation can be found especially in
the case of VEP and BAEP analyses. Also in the current
study, abnormalities in BAEP, VEP and SEP were found
in a large percentage of asymptomatic patients. Several
potential explanations for this disproportion have been
proposed so far in the literature. Newman et al. ex-
plained from the ophthalmologic side that excellent
visual acuity is usually retained despite marked neuroo-
cular dysfunction [21]. Therefore, there is a wide margin
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for subclinical damage of the visual pathway. Subclin-
ical abnormalities in BAEP can be explained by the
subclinical functional defect of cochlea induced by a
radiation [12].
In our study, we analyzed ALL long-term survivors,
aged 4.9–28.4 years. Therefore, all our patients were at
the age at which common comorbidities such as diabetes
and hypertension, which may contribute to further loss
of nerve fibers, are not common [21]. Furthermore, as
has been shown many times, long-term ALL survivors
are a high-risk group for developing diabetes [22] as well
as hypertension [23]. For this reason, we hypothesized
that the one-time screening with EP presented by us will
allow to separate a group of patients at increased risk of
developing clinically apparent visual, hearing or sensory
impairment. Currently, there is no research in the litera-
ture that could confirm this initial hypothesis. For this
reason, longer observations also involving genetic
methods useful in the pediatric population [24, 25] are
necessary.
Neurophysiological assessment allows to make evalu-
ation of patient health objective. As EP is noninvasive
method, it can be repeatedly performed, being good in-
dicator of recovery or progression. It seems to be the
best tool to neurologic late effects monitoring. EP allows
to detect changes even many years after completing of
therapy. Together with precise clinical evaluation EP al-
lows to correct the conclusions from individual evalu-
ation of students and their professional activation
opportunities after ALL therapy. High prevalence of de-
tected abnormalities in the neurophysiological assess-
ments indicates necessity of its monitoring in prolonged
follow-up after treatment. Although observed abnormal-
ities are not severe, they can explain lower psychophys-
ical capacity of youth entering adult life, being treated
for years with multimodal chemotherapy/radiotherapy
during childhood. Questionnaires used in many study
protocols, evaluating quality of life are very useful in the
assessment. Unfortunately subtle peripheral and central
nervous system dysfunctions may not be detected, and
patients can be unjustly treated by society as persons
psychophysically healthy. Therefore precise clinical
evaluation should be in accordance with indications
replenished by other neurophysiological technics, includ-
ing evoked potentials.
Our study has several limitations. First, the analyzed
patient groups differed in terms of age. However, it has
been shown that age is not a significant factor modulat-
ing EP [26]. Second, in our study we analyzed asymp-
tomatic patients. Therefore, we could not compare the
results of the EP analysis with the abnormalities in the
neurological examination. Third, in the current study we
analyzed ALL protocols used in clinical practice in the
past. However, only such an analysis made it possible to
verify the impact of radiotherapy on EP, which was one
of the objectives of our studies [27].
Conclusions
The oncological treatment had a significant impact on
the shape of registered EP. The presented analysis indi-
cates a high frequency of subclinical abnormalities in EP
regardless of the analyzed protocol. To our knowledge
current study is the largest and one of the most complex
research with the longest follow-up time examining the
role of EP in ALL patients. The obtained results indicate
the possibility of using a single, objective and non-
invasive measurement of EP in ALL survivors in order
to stratify the risk of developing sensory abnormalities in
adulthood.
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